0001906324-26-000008
SEC filingRevenue declined 2% to $2.73B due to respiratory product variability, offset by cost savings and segment growth.
QuidelOrtho Corporation is a diagnostics company whose vision is to advance diagnostics to power a healthier future. The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine. It serves customers in over 140 countries and territories, with manufacturing facilities in the U.S., U.K., and China. The company operates globally with sales centers, administrative offices, and warehouses worldwide.
The company manages its business geographically and has five reportable segments: North America, EMEA, China, JPAC, and Latin America. Revenue is generated through four business units: Labs, Transfusion Medicine (Immunohematology and Donor Screening product categories), Point of Care, and Molecular Diagnostics. Non-core revenue includes contract manufacturing and business collaborations. The wind-down of the U.S. donor screening portfolio (VIP platform and microplate assays) was initiated in February 2024 and is expected to be substantially complete by the first half of 2026.
The Labs business unit includes the VITROS platform (clinical chemistry and immunodiagnostics), VITROS XT platform, and informatics software. Molecular Diagnostics offers the LYRA, SOLANA, and SAVANNA platforms (SAVANNA development was discontinued in Q2 2025). Point of Care includes SOFIA, SOFIA 2, QUICKVUE, TRIAGE, and TRIAGE METERPRO platforms. Transfusion Medicine includes the ORTHO VISION platform, ORTHO OPTIX, ID-Micro Typing System Gel Cards, BIOVUE Cassettes, and ORTHO Sera Reagents. Services include e-connectivity, VALUMETRIX consulting, global technical support, and digital solutions like QuidelOrtho RESULTS MANAGER.
The company sells products directly to end users through a direct sales force and a network of distributors. In developed markets (North America, Western Europe), direct sales are primary; in emerging markets (China, Asia Pacific, Middle East, Africa, Eastern Europe, Latin America), a combination of direct and distributor models is used. The sales team consists of over 2,500 employees in sales, service, and marketing. In fiscal 2025, one customer represented 11% of total revenues. The company also has a collaboration with Grifols for Hepatitis and HIV diagnostics, which is being terminated with a $65 million charge.
The in vitro diagnostics market is highly competitive. Key competitors include Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters Corporation (acquired BD Diagnostics division), and Wermerson Immuncor. Competitive factors include convenience, speed, product menu, price, reimbursement, and service. The company believes its strengths include superior customer experience, brand loyalty, strong commercial footprint, POC leadership, manufacturing scale, and robust R&D.
The company's strategy focuses on economic profit and return on invested capital. Near-term priorities include increasing market share in high-value profit pools, building a culture for sales growth and profitability, aligning incentives with value creation, and talent management. Longer-term plans involve enhancing customer service, investing in platform capabilities and assay menus, and exploring collaborations. The company also emphasizes innovation through R&D, with expenses of $186.2 million in fiscal 2025.
As of December 28, 2025, QuidelOrtho had approximately 6,500 employees worldwide (3,600 in the U.S., 2,900 outside). Manufacturing employees number about 2,100, and commercial sales, service, and marketing employees number about 2,500 (including 1,200 service employees). Approximately 16% of global associates are covered by union or collective bargaining agreements. The company emphasizes inclusion, employee benefits, health and safety, and sustainability.
For fiscal 2025, total revenue decreased 2% to $2,730.2 million from $2,782.9 million in 2024, primarily due to a $104.7 million decline in COVID-19 sales and the wind-down of the U.S. donor screening portfolio. Labs revenue grew 6% to $1,505.7 million, driven by reagents, consumables, and services, while Immunohematology increased 4% to $543.8 million. Donor Screening plummeted 54% to $52.6 million as the exit progressed. Point of Care fell 13% to $601.6 million due to lower SARS antigen assay sales. Molecular Diagnostics rose 10% to $26.5 million. Gross margin improved to 46.7% from 46.2%, benefiting from procurement cost-savings. Selling, marketing, and administrative expenses dropped 2.7% to $746.3 million, and R&D spending fell 14.9% to $186.2 million, both reflecting cost-reduction initiatives. However, restructuring charges surged to $263.6 million (including the Optimization Plan), and a $700.7 million goodwill impairment was recorded, leading to a net loss of $1,131.8 million, though improved from a $2,052.0 million loss in 2024.
North America revenue declined 8% to $1,488.9 million, hit by lower Point of Care sales and the donor screening wind-down, partially offset by Labs growth. Adjusted EBITDA fell 10% to $807.0 million. EMEA posted strong 7% revenue growth to $360.7 million, with Immunohematology and Point of Care gains, and Adjusted EBITDA surged 78% to $82.6 million due to mix and cost controls. China grew 3% to $334.7 million, driven by Labs but partly offset by Donor Screening and Immunohematology declines; Adjusted EBITDA rose 8% to $141.2 million. JPAC increased 5% to $293.0 million on Labs and Immunohematology strength; Adjusted EBITDA rose 5% to $73.2 million. Latin America led with 13% growth to $252.9 million, fueled by Labs, and Adjusted EBITDA jumped 23% to $78.4 million.
Management expects overall demand for respiratory and non-respiratory products to fluctuate, with respiratory seasonality remaining variable. The U.S. donor screening wind-down should be substantially complete by first half of 2026. The multi-year Optimization Plan aims for $50 million in net cost savings by 2027, with aggregate pre-tax charges of approximately $100 million. Recent U.S. tariffs have introduced incremental costs, but the company has largely offset them via supply chain adjustments; further tariffs could materially impact results. The company remains focused on expanding reagent rental placements and strategic investments to drive long-term growth.
As of December 28, 2025, the company held $169.8M in cash and cash equivalents, with total debt of $2,650.2M (including $1,150.0M Term Loan A, $1,450.0M Term Loan B, $80.0M revolver, and other borrowings). Shareholders' equity was $1,920.5M, down 35.6% from $2,984.5M a year earlier, driven by a net loss of $1,131.8M and cumulative translation adjustments. Inventory was $577.6M (current), and total deferred revenue was $54.7M ($37.8M current, $16.9M non-current). Goodwill was fully impaired, leaving $0 balance.
Purchase obligations totaled $236.9M as of year-end 2025, primarily related to inventory and service commitments, with the majority expected to be paid within one year. The company also has royalty and license expenses of $14.0M in 2025. Operating lease commitments amount to $212.2M in undiscounted payments, with $183.7M recognized as lease liabilities. No other material contractual obligations were disclosed.
There were no share repurchases in 2025; the prior $300M authorization expired in August 2024. No dividends were paid. The company refinanced its debt in August 2025, issuing $1.15B Term Loan A and $1.45B Term Loan B, using proceeds to repay the previous $2.28B term loan and $490M revolver. Net debt increased by $167M. Capital expenditures were $188.2M (6.9% of revenue), primarily for instruments placed under reagent rental agreements and facility improvements.
The company operates in five geographic segments. North America generated $1,488.9M (54.5% of total revenue), down 8.1% YoY, with segment Adjusted EBITDA margin of 54.2%. EMEA revenue grew 7.4% to $360.7M (margin 22.9%). China revenue grew 3.0% to $334.7M (margin 42.2%). JPAC revenue grew 4.9% to $293.0M (margin 25.0%). Latin America grew 13.5% to $252.9M (margin 31.0%). Total segment Adjusted EBITDA was $1,182.4M, down 1.7% from $1,202.6M in 2024, with corporate and other charges leading to an operating loss.
QuidelOrtho's Risk Factors section for fiscal year 2025 is comprehensive, covering competitive dynamics, operational vulnerabilities, financial leverage, and regulatory challenges. Key themes include reliance on respiratory product sales (15% of revenue), high debt of $2.65 billion, and supply chain disruptions from tariffs. The company is executing an Optimization Plan with $100 million in expected charges through 2027 to achieve $50 million in net cost savings.
The diagnostics industry is intensely competitive, with larger players possessing greater resources. The company faces risks from customer consolidation (e.g., group purchasing organizations and China's VBP program) and long contract cycles (5–7 years), which can lock out opportunities. Failure to innovate is exemplified by the discontinuation of the SAVANNA platform.
Supply chain disruptions are exacerbated by U.S. tariffs imposed in April 2025, causing incremental costs. The company relies on single- and sole-source suppliers for critical materials, and manufacturing is concentrated in facilities near earthquake zones (California) and other vulnerable areas. Respiratory product demand is highly seasonal and subject to market share shifts.
With $2.65 billion in total debt, interest rate increases on variable-rate borrowings could materially impact cash flows. The credit agreement imposes restrictive covenants, including leverage and interest coverage ratios. The reagent rental model further strains near-term cash flows.
Respiratory products are marketed under EUAs; loss of these authorizations could remove products from the market if traditional clearance is not obtained. Ongoing regulatory scrutiny (FDA, foreign agencies) and evolving healthcare laws (anti-kickback, false claims) pose litigation and penalty risks. AI adoption introduces additional regulatory uncertainty.
Cybersecurity threats are heightened by remote work and sophisticated attacks. While no material incidents have occurred, a breach could disrupt operations and result in liability. Reliance on third-party cloud providers and interoperability with mobile OS platforms present additional vulnerabilities.
Global operations expose the company to currency fluctuations, geopolitical conflicts (Ukraine, Middle East), and trade sanctions. Compliance with diverse regulations (e.g., China anti-corruption campaign) adds complexity. Tariff and trade policy uncertainty remains high.
Overall, the risk profile reflects a company navigating a competitive, regulated, and capital-intensive industry with significant operational leverage. The Optimization Plan aims to improve efficiency, but execution risk remains.
The provided excerpt does not contain the actual cash flow statement numbers. It only includes the audit report and index. Therefore, no cash flow analysis can be performed.